Skip to main content

Research Repository

Advanced Search

Outputs (25)

High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only (2024)
Journal Article
Sculthorpe, D. J., Denton, A., Fadhil, W., Rusnita, D., Ilyas, M., & Mukherjee, A. (2024). High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only. American Journal of Clinical Pathology, https://doi.org/10.1093/ajcp/aqae145

Objectives
As mismatch repair status confers differential prognosis in colorectal cancers, this study aimed to determine associations of α–smooth muscle actin (α-SMA) protein expression in mismatch repair–proficient (pMMR) and mismatch repair–defici... Read More about High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only.

Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer (2024)
Journal Article
Sculthorpe, D., Denton, A., Rusnita, D., Fadhil, W., Ilyas, M., & Mukherjee, A. (2024). Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer. Pathology - Research and Practice, 260, Article 155470. https://doi.org/10.1016/j.prp.2024.155470

As pathology moves towards digitisation, biomarker profiling through automated image analysis provides potentially objective and time-efficient means of assessment. This study set out to determine how a complex membranous immunostain, E-cadherin, ass... Read More about Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer.

Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids (2022)
Journal Article
Babaei-Jadidi, R., Kashfi, H., Alelwani, W., Bakhtiari, A., Kattan, S. W., Mansouri, O. A., Mukherjee, A., Lobo, D. N., & Nateri, A. S. (2022). Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids. Oncogenesis, 11, Article 4. https://doi.org/10.1038/s41389-021-00376-1

Little is known about the role of microRNAs (miRNAs) in rewiring the metabolism within tumours and adjacent non-tumour bearing normal tissue and their potential in cancer therapy. This study aimed to investigate the relationship between deregulated m... Read More about Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids.

Zanubrutinib-induced liver injury: a case report and literature review (2021)
Journal Article
Atallah, E., Wijayasiri, P., Cianci, N., Abdullah, K., Mukherjee, A., & Aithal, G. P. (2021). Zanubrutinib-induced liver injury: a case report and literature review. BMC Gastroenterology, 21(1), Article 244. https://doi.org/10.1186/s12876-021-01825-2

Background: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of... Read More about Zanubrutinib-induced liver injury: a case report and literature review.

High tissue inhibitor of matrix-metalloproteinase 2 expression correlates with poor prognosis in breast cancer (2020)
Presentation / Conference Contribution
Heyman, T., Joseph, C., Craze, M., Green, A., Nolan, C., Rueda, O., Provenzano, E., Rakha, E., Ellis, I. O., & Mukherjee, A. (2020, December). High tissue inhibitor of matrix-metalloproteinase 2 expression correlates with poor prognosis in breast cancer. Presented at 32nd Congress of the ESP and XXXIII International Congress of the IAP, Glasgow, UK (virtual)

Background & objectives
TIMP2, tissue inhibitor of matrix-metalloproteinase 2, inhibits the matrix-metalloproteinase, MMP2, but may activate pro-MMP2. Hence its correlation with prognosis in breast cancer (BC) is contradictory. This study investigat... Read More about High tissue inhibitor of matrix-metalloproteinase 2 expression correlates with poor prognosis in breast cancer.

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells (2020)
Journal Article
Boonsri, B., Yacqub-Usman, K., Thintharua, P., Myint, K. Z., Sae-Lao, T., Collier, P., Suriyonplengsaeng, C., Larbcharoensub, N., Balasubramanian, B., Venkatraman, S., Egbuniwe, I. U., Gomez, D., Mukherjee, A., Kumkate, S., Janvilisri, T., Zaitoun, A. M., Kuakpaetoon, T., Tohtong, R., Grabowska, A. M., Bates, D. O., & Wongprasert, K. (2020). Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells. Cancer Research and Treatment, 53(2), 457-470. https://doi.org/10.4143/crt.2020.585

Purpose The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in pati... Read More about Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells.

Repurposing Antibacterial AM404 as a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells (2019)
Journal Article
Ahmed, M., Jinks, N., Babaei-Jadidi, R., Kashfi, H., Castellanos-Uribe, M., May, S. T., Mukherjee, A., & Nateri, A. S. (2019). Repurposing Antibacterial AM404 as a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells. Cancers, 12(1), Article 106. https://doi.org/10.3390/cancers12010106

Tumour-promoting inflammation is involved in colorectal cancer (CRC) development and therapeutic resistance. However, the antibiotics and antibacterial drugs and signalling that regulate the potency of anticancer treatment upon forced differentiation... Read More about Repurposing Antibacterial AM404 as a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells.

IgG4 Expression Correlates with Poor Prognosis in Pancreatic Adenocarcinoma (2019)
Presentation / Conference Contribution
Budd, W., Mukherjee, A., Lobo, D., & Zaitoun, A. (2019, July). IgG4 Expression Correlates with Poor Prognosis in Pancreatic Adenocarcinoma. Presented at Leeds Pathology 2019. 12th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 2–4 July 2019, Leeds, England

Purpose of the study: IgG4, a member of the immunoglobulin family, has been implicated in the pathobiology of inflammatory disease (including autoimmune pancreatitis) and cancers. Its role in pancreatic cancers however remains to be elucidated. This... Read More about IgG4 Expression Correlates with Poor Prognosis in Pancreatic Adenocarcinoma.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion (2018)
Journal Article
Sonbul, S. N., Aleskandarany, M. A., Kurozumi, S., Joseph, C., Toss, M. S., Diez-Rodriguez, M., Nolan, C. C., Mukherjee, A., Martin, S., Caldas, C., Ellis, I. O., Green, A. R., & Rakha, E. A. (in press). Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. Modern Pathology, https://doi.org/10.1038/s41379-018-0092-9

Lymphovascular invasion is strongly related to breast cancer metastasis. However, the underlying mechanisms of lymphovascular invasion and its driver molecules in breast cancer remain to be defined. In this study, we explore differential expression o... Read More about Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes (2018)
Journal Article
Joseph, C., Macnamara, O., Craze, M., Russell, R., Provenzano, E., Nolan, C. C., Diez-Rodriguez, M., Sonbul, S. N., Aleskandarany, M. A., Green, A. R., Rakha, E. A., Ellis, I. O., & Mukherjee, A. (in press). Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. British Journal of Cancer, https://doi.org/10.1038/s41416-018-0041-x

Background: Mediator complex (MED) proteins have a key role in transcriptional regulation, some interacting with the oestrogen receptor (ER). Interrogation of the METABRIC cohort suggested that MED7 may regulate lymphovascular invasion (LVI). Thus ME... Read More about Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.